 |
 Video: What is a Stock Split?
|
|
|
| Sensei Biotherapeutics is an immuno-oncology company focused on the discovery and development of therapeutics for cancer patients. Through its Tumor Microenvironment Activated Biologics platform, Co. is developing therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals in the tumor microenvironment. Co.'s product candidates: SNS-101, which is Co.'s monoclonal antibody targeting the immune checkpoint V-domain Ig suppressor of T-cell activation; SNS-102, which is Co.'s monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4; and SNS-103, which is Co.'s monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1. According to our Sensei Biotherapeutics stock split history records, Sensei Biotherapeutics has had 0 splits. | |
|
Sensei Biotherapeutics (SNSE) has 0 splits in our Sensei Biotherapeutics stock split history database.
Looking at the Sensei Biotherapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Sensei Biotherapeutics shares, starting with a $10,000 purchase of SNSE, presented on a split-history-adjusted basis factoring in the complete Sensei Biotherapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
02/05/2021 |
|
| End date: |
04/25/2024 |
|
| Start price/share: |
$22.49 |
|
| End price/share: |
$1.00 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-95.55% |
|
| Average Annual Total Return: |
-62.01% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$444.66 |
|
| Years: |
3.22 |
|
|
|
|
|
